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Background: The aim of our study was to assess the relationship between soluble
Klotho (s-Klotho) and carotid intimaemedia thickness (CIMT) and left ventricular
(LV) dysfunction in hemodialysis (HD) patients.
Methods: This is a cross-sectional study conducted on 88 patients with end-stage
renal disease on regular HD. Serum levels of calcium, phosphorus, parathyroid
hormone, and C-reactive protein were measured. The serum levels of s-Klotho and
ﬁbroblast growth factor-23 (FGF-23) were measured using an Enzyme linked
immunosorbent assay (ELISA) kit. Echocardiography and measurement of CIMT
were also conducted. The studied patients were divided according to the median s-
Klotho level into 2 groups: patients with low s-Klotho (Group I) and patients with
high s-Klotho (Group II).
Results: Mean value of s-Klotho was signiﬁcantly low in HD patients compared to
controls (P ¼ 0.001), and mean value of FGF-23 was signiﬁcantly high in HD patients
compared to controls (P ¼ 0.001). The mean values of parathyroid hormone, FGF-23,
and phosphorus were signiﬁcantly high in Group I compared to Group II, whereas
the mean value of serum calcium was signiﬁcantly low in Group I compared to
Group II. The mean values of CIMT, LV mass (LVM), LVM index, and LV ejection
fraction (LVEF) were high in Group I compared to Group II. Patients with low s-
Klotho had signiﬁcantly more coronary artery disease (CAD). In a regression analysis
of s-Klotho with different markers of cardiovascular diseases, s-Klotho showed
signiﬁcant association with CIMT, LVEF, and CAD, but not with LVM and LVM index.
Conclusion: The present study showed that patients with a low s-Klotho were
more often associated with increased CIMT, LV dysfunction, and CAD, and it seems
that there was independent association between s-Klotho and CIMT, LVEF, and CAD.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).arch Institute, El-Nile Street, Waraq El-Hadar, P.O. Box 30, Imbaba, Giza 12411, Egypt.
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Chronic kidney disease (CKD) is associated with increased
levels of parathyroid hormone (PTH) and ﬁbroblast growth
factor-23 (FGF-23) and hypocalcemia, hyperphosphatemia,
bone disease, vascular calciﬁcation, and cardiovascular mor-
bidities collectively referred to as CKD-mineral and bone
disorder [1e3]. Recent reports suggested that increased levels
of FGF-23 and decreased levels of soluble Klotho (s-Klotho) are
common manifestations of CKD that develop earlier than
increased levels of phosphate (Ps) or PTH [4,5].
A transmembrane (TM) protein known as soluble a-Klotho
(s-Klotho) is primarily produced in the kidney distal tubular
cells [6]. Soluble a-Klotho acts as a coreceptor for the bone-
derived protein FGF-23 [7,8]. Regulation of both renal handling
of Ps and renal synthesis of calcitriol needs a cofunction of both
FGF-23 and TM-Klotho [9]. Soluble a-Klotho is the circulating
protein resulting from the shedding of the extracellular domain
of TM-Klotho operated by 2 metalloproteinases of the A dis-
integrin and metalloproteinase domainecontaining protein
(ADAM) family: ADAM10 and ADAM17 [10]. In particular, s-
Klotho inhibits the sodium-Ps cotransporter NaPi2a expression
in the proximal tubules, thus generating a phosphaturic effect
additive to and independent of FGF-23 [11e13], and activates
the ion channel TRPV5 in the distal tubules, thus increasing
tubular reabsorption of calcium (Ca) [14]. Therefore, a-Klotho,
with its TM and soluble forms, is deeply involved with the
physiological regulation of mineral metabolism [15].
CKD is a common risk factor for cardiovascular diseases
(CVD) such as coronary artery disease (CAD), cerebrovascular
stroke, peripheral vascular disease, and heart failure [16].
Although part of CVD burden in patients with CKD is related to
traditional risk factors, CKD-associated disturbance in CaePs
homeostasis plays a crucial role as well [2]. Recent studies
showed that FGF-23 and its coreceptor s-Klotho have an
important role in CaePs homeostasis, and they could be the
missing link in the detrimental relationship between CKD and
CVD [17].
Given the strong cardioprotective effects of Klotho demon-
strated in preclinical studies, the present study aimed to assess
the association between s-Klotho and carotid intimaemedia
thickness (CIMT) and left ventricular (LV) dysfunction in pa-
tients with end-stage renal disease (ESRD) on regular hemo-
dialysis (HD). It was hypothesized that low levels of s-Klotho
are associated with a larger burden of CVD in these patients.
Methods
Study population
This is a cross-sectional study conducted on 88 patients with
ESRD on regular HD of at least 6-month duration. All patients
have been attending the nephrology dialysis unit in the Theo-
dor Bilharz Research Institute, Giza, Egypt. All patients received
3 sessions of HD/wk, each of 4-hour duration using a poly-
sulfone dialyzer (Fresenius, St. Wendel, Germany) with surface
area of 1.4e1.6. Patients with advanced congestive heart failure
[deﬁned clinically by elevated jugular venous pressure, ascites,
peripheral edema, and shortness of breath at rest and LV
ejection fraction (LVEF) of <30% in echocardiography requiring
hospital-based support, a heart transplant, or palliative care
according to guidelines of the American College of Cardiology/American Heart Association] [18], sepsis, or malignancy were
excluded from the study. Informed written consent was ob-
tained from all participants. The study protocol was approved
by the institute ethics committee, and the study was performed
in accordance with the Declaration of Helsinki.
The studied patients were divided according to the median
s-Klotho level (cut point, 476 pg/mL) into 2 groups: patients
with low s-Klotho <476 pg/mL (Group I, n ¼ 44) and patients
with high s-Klotho >476 pg/mL (Group II, n ¼ 44).
A control group consisting of 28 normal individuals was used
to give our reference values for s-Klotho, FGF-23, CIMT, and
echocardiographic ﬁndings. There were 17 men and 11 women
with a mean age of 53.3± 16.2 years, with normal renal
function and no evidence of acute or chronic underlying disease.
Each patient underwent a thorough history and clinical
examination. Demographic characteristics and coexisting
conditions such as atherosclerotic CAD diagnosed by electro-
cardiography and coronary angiography within 3 months of
enrollment in the study were collected.
Fasting blood samples were collected from the patients
before the HD session, immediately centrifuged, aliquoted in
vials, and stored at e60C until the time of analysis. Thawing
the test samples was carried out at a low temperature by
mixing them completely before measurement. Routine exam-
inations included complete blood analysis, kidney function
tests (serum urea, creatinine, sodium and potassium, and uric
acid), random blood sugar, serum electrolytes, lipid proﬁle, and
serum albumin. Serum levels of Ca, Ps, PTH, and C-reactive
protein were measured.
Serum levels of s-Klotho and FGF-23 measurement
The serum levels of s-Klotho were measured using an
Enzyme linked immunosorbent assay (ELISA) system
(Immuno-Biological Laboratories, Gunma, Japan) [19], and this
assay detects circulating s-Klotho using 2 monoclonal anti-
bodies that speciﬁcally recognize the extracellular domain of
Klotho, with a lower limit of detection of 6.15 pg/mL and the
intra-assay and interassay coefﬁcients of variation of <10%. The
serum levels of FGF-23 were measured using a commercial
sandwich ELISA kit (Kainos Laboratories, Inc., Tokyo, Japan)
[20] that uses a 2-site ELISA for the full-length molecule. Two
speciﬁc murine monoclonal antibodies recognize the biologi-
cally active FGF-23, with a lower limit of detection of
3 pg/mL and interassay and intra-assay coefﬁcients of variation
of <5%.
Residual renal function estimation
Residual renal function (RRF) was estimated by calculating
glomerular ﬁltration rate expressed in mL/min/1.73m2.
Glomerular ﬁltration rate was estimated as the mean of urea
and creatinine clearance using 24-hour urine collections and
the mean of the post- and pre-HD plasma urea and creatinine.
RRF was considered zero in patients with a urinary output
<100 mL/24 h [21]. Kt/V was used to assess dialysis adequacy
[22].
Echocardiography
After the HD session, each patient underwent echocardiog-
raphy to determine LVmass (LVM), LVM index (LVMI), and LVEF.







Age (y) 58.6 ± 19.3 53.3 ± 16.2 0.192
Gender (M/F) 51/37 (58.0/42.1) 17/11 (60.7/39.3) 1.000
BMI (g/m2) 24.6 ± 5.2 26.2 ± 5.6 0.167
SBP (mmHg) 124.6 ± 15.5 119.2 ± 11.3 0.091
DBP (mmHg) 85.7 ± 25.4 80.4 ± 19.1 0.312
Mean BP (mmHg) 98.7 ± 28.8 93.4 ± 22.6 0.376
Duration of
dialysis (mo)
59.5 ± 35.4 e e









Data are presented as means ± SD or number (%).
APKD, adult polycystic kidney disease; BMI, body mass index; BP, blood
pressure; CIN, chronic interstitial nephritis; DBP, diastolic blood pres-
sure; DM, diabetes mellitus; ESRD, end-stage renal disease; GN,
glomerulonephritis; HTN, hypertension; SBP, systolic blood pressure;
SLE, systemic lupus erythematosus.
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LVM (g): 1.04 [(LVID þ PWT þ IVST)3 e LVID3] e 14, where LVID
indicates LV internal dimension, PWT indicates posterior wall
thickness, and IVST indicates interventricular septal thickness.
LVM was divided by body surface area to measure LVMI. Ac-
cording to the current guidelines, LV dysfunction was deﬁned
as an LVEF < 45%.
Measurement of CIMT
After the HD session, each patient underwent ultrasonog-
raphy of the carotid arteries using a high-resolution real-time
scanner with a 7.5-MHz transducer [24]. The examination
was done with the patient in the supine position, and the
common carotid artery and carotid bifurcation were scanned
on both sides. The carotid artery was scanned in the longitu-
dinal and transverse directions. The site of the most advanced
atherosclerotic lesion that showed the greatest distance be-
tween the lumeneintima interface and the mediaeadventitia
interface was the maximum intimaemedia thickness (IMT)
value. When plaque was detected on ultrasonography, it was
observed as localized thickening rather than a circumferential
change in the vessel wall. The greatest thickness of the
intimaemedia complex (including plaque) was used for the
maximum IMT value. We identiﬁed patients having athero-
sclerosis based on atheromatous plaques of focal increases in
IMT 1.1 mm in accordancewith a prior study that showed the
normal limit of IMT to be 1.0 mm [25].
Statistical analysis
Data are presented asmeans± SD or number (%). The 2-tailed
Student's t testwas used to compare themeanvalues of 2 groups
(GraphPad Quick calc; Graphpad Software Inc., San Diego, CA,
USA). Categorical data were compared using the chi-square test.
The Spearman rank correlation test was used to analyze the
correlations between s-Klotho levels and markers of mineral
metabolism. Multivariate regression analysis (using MedCalc
software; MedCalc software bvba, Acacialaan, Ostend, Belgium)
was used to analyze the association between s-Klotho and
markers of CVD, with a linear regression analysis model with
unstandardizedbetas anda95%conﬁdence interval (CI) for CIMT,
LVM, LVMI, and LVEFand a logistic regression analysismodelwas
used for CAD. The linear regression analysismodelwas also used
to determine the association between FGF-23 and CIMT, LVM,
LVMI, and LVEF and the logistic regression analysis model was
used for CAD. Statistical analyses of data were performed using
SPSS for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA). A
P value< 0.05 was considered to be signiﬁcant, and P < 0.01 was
considered to be highly signiﬁcant.
Results
Demographic characteristics of HD patients and controls
included in this study are shown in Table 1, where the mean age
of studied patients was 58.6 ± 19.3 years. Fifty-one (58.0%) pa-
tientsweremen and 37 (42.1%) werewomen. Themost common
causes of ESRD were diabetes mellitus, hypertension, and
glomerulonephritis (Table 1).
Mean value of s-Klotho was signiﬁcantly low in HD patients
compared to the control group (477.9± 76.2 vs. 863.7± 261.8,
P ¼ 0.001), and mean value of FGF-23 was signiﬁcantly high inHD patients compared to the control group (60.5± 17.6 vs.
35.8± 13.9, P ¼ 0.001; Table 2).
Patients with a low s-Klotho (<476 pg/mL) were older
(63.2± 9.4 vs. 53.8± 16.2, P¼ 0.001) and had high FGF-23, PTH,
Ps, and C-reactive protein and low Ca and RRF (Table 2)
compared to Group II. There were no signiﬁcant differences in
the mean values of serum creatinine, lipid proﬁle, hemoglobin,
serum glucose, serum albumin, serum uric acid, and Kt/V be-
tween the 2 groups (Table 2).
s-Klotho and markers of mineral metabolism
Themean values of serum levels of PTH, FGF-23, and Ps were
signiﬁcantly high in patients of Group I compared to patients of
Group II, whereas the mean value of serum levels of Ca was
signiﬁcantly low in Group I compared to Group II (Table 2).
Using the Spearman rank correlation test, we found that
there was signiﬁcant negative correlation between s-Klotho
and FGF-23 (r ¼ e0.717, P ¼ 0.001, 95% CI for r ¼ e0.806 to
e0.598; Fig.1), PTH (r¼e0.484, P¼ 0.001, 95% CI for r¼e0.630
to e0.306; Fig. 2), and Ps (r ¼ e0.548, P ¼ 0.001, 95% CI e0.680
to e0.383; Fig. 3), whereas there was signiﬁcant positive cor-
relation between s-Klotho and Ca (r ¼ 0.294, P ¼ 0.005, 95% CI
0.0903e0.474; Fig. 4).
s-Klotho and markers of CVD
The mean values of CIMT, LVM, LVMI, and LVEF were high in
patients of Group I compared to patients of Group II. The
prevalence of CAD was higher among patients with low s-
Klotho [36 (81.1%) vs. 22 (50.0%), P ¼ 0.004; Table 3].
Using the Spearman rank correlation test, we found that
there was signiﬁcant positive correlation between s-Klotho and
LVEF (r ¼ 0.392, 95% CI 0.199e0.556, P ¼ 0.001; Fig. 5).
Table 4 shows the results of the multivariate regression
analysis of s-Klotho with CIMT, LVM, LVMI, LVEF, and CAD as
different markers for CVD. After adjustments for age, gender,
mean blood pressure, and duration of HD, s-Klotho showed






(s-Klotho < 476 pg/mL, n ¼ 44)
Group II
(s-Klotho > 476 pg/mL, n ¼ 44)
P
sCr (mg/dL) 7.9 ± 1.8 0.8 ± 0.3 0.001 7.5 ± 1.2 8.3 ± 3.1 0.114
S. Ca (mg/dL) 8.4 ± 1.0 8.5 ± 0.6 0.618 8.1 ± 0.8 8.7 ± 1.3 0.014
S. Ps (mg/dL) 1.9 ± 1.1 0.9 ± 0.2 0.001 2.1 ± 0.5 1.8 ± 0.6 0.013
S. PTH (pg/mL) 71.7 ± 25.1 31.2 ± 23.4 0.001 76.9 ± 21.3 67.1 ± 24.5 0.048
RRF (mL/min/1.73 m2) 2.1 ± 1.5 2.4 ± 1.8 3.1 ± 1.3 0.040
Kt/V 1.6 ± 0.6 1.5 ± 0.4 1.6 ± 0.5 0.101
T. cholesterol (mg/dL) 154.4 ± 16.4 122.3 ± 14.6 0.001 151.4 ± 17.4 148.3 ± 17.3 0.404
LDL-C (mg/dL) 123.3 ± 37.3 101.5 ± 27.8 0.005 124.4 ± 36.8 122.2 ± 36.6 0.779
TGs (mg/dL) 116.5 ± 20.5 91.7 ± 16.3 0.001 117.7 ± 22.3 115.3 ± 19.2 0.590
Hb (g/dL) 11.2 ± 1.5 13.8 ± 1.2 0.001 10.8 ± 1.5 11.2 ± 1.4 0.199
Bl. glucose (mg/dL) 136.7 ± 26.4 118.6 ± 21.3 0.001 132.1 ± 27.3 141.4 ± 25.8 0.102
C-RP (mg/L) 16.1 ± 4.2 0.71 ± 0.4 0.001 20.9 ± 5.1 17.3 ± 6.2 0.004
S. albumin (g/dL) 3.8 ± 0.7 4.2 ± 0.6 0.008 3.7 ± 0.4 3.9 ± 0.9 0.182
S. uric acid (mg/dL) 6.8 ± 1.0 5.7 ± 1.2 0.001 6.7 ± 0.7 7.1 ± 1.4 0.094
S-Klotho (pg/mL) 477.9 ± 76.2 863.7 ± 261.8 0.001 427.8 ± 46.2 535.4 ± 61.4 0.001
S. FGF-23 (pg/mL) 60.5 ± 17.6 35.8 ± 13.9 0.001 67.8 ± 24.2 50.3 ± 11.2 0.001
Data are presented as mean ± SD.
Bl., blood; Ca, calcium; C-RP, C-reactive protein; FGF-23, ﬁbroblast growth factor-23; Hb, hemoglobin; LDL-C, low-density lipoprotein cholesterol;
Ps, phosphorus; PTH, parathyroid hormone; RRF, residual renal function; S., serum; sCr, serum creatinine; s-Klotho, soluble Klotho; T., total; TG,
triglyceride.
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LVM and LVMI.FGF-23 and markers of mineral metabolism
Using the Spearman rank correlation test, we found that
there was positive correlation between FGF-23 and Ps
(r ¼ 0.497, P ¼ 0.001, 95% CI 0.321e0.640) and PTH (r ¼ 0.405,
P ¼ 0.001, 95% CI 0.214e0.567), whereas there was negative
correlation between FGF-23 and Ca (r ¼ e0.237, P ¼ 0.026, 95%
CI e0.426 to e0.029).FGF-23 and CVD markers
Table 4 shows the results of multivariate regression models
of FGF-23, total cholesterol, triglycerides, and blood glucose
with CIMT, LVM, LVMI, LVEF, and CAD as different markers for
CVD. After adjustments for age, gender, mean blood pressure,
and duration of HD, FGF-23, total cholesterol, triglycerides, andFigure 1. Correlation coefﬁcient between the serum level of s-Klotho and F
FGF-23, ﬁbroblast growth factor-23; s-Klotho, soluble Klotho.blood glucose were not independently associated with CIMT,
LVM, LVMI, LVEF, and CAD.
Discussion
In the present study, we measured the s-Klotho levels and
determined the association between s-Klotho levels and
markers of mineral metabolism (FGF-23, PTH, Ca, and Ps) and
CVD (CIMT, CAD, LVM, LVMI, and LVEF) in patients with ESRD on
regular HD. Our study showed that there was signiﬁcant
negative correlation between s-Klotho levels and serum levels
of FGF-23, PTH, and Ps and positive correlation between
s-Klotho and serum levels of Ca. In addition, the present study
showed that lower levels of s-Klotho are signiﬁcantly associ-
ated with signs of CVD such as increased CIMT, more CAD, and
LV dysfunction.
Our study showed that serum levels of s-Klotho were
signiﬁcantly decreased in patients with ESRD on regular HD
compared to the control group, as previously reported in CKD
patients [26] and patients on HD [27e29]. It has been reportedGF-23. r ¼ e0.717, 95% conﬁdence interval, e0.806 to e0.598, P ¼ 0.001.
Figure 3. Correlation coefﬁcient between the serum levels of s-Klotho and Ca. r ¼ 0.294, 95% conﬁdence interval 0.0903e0.474, P ¼ 0.005.
Ca, calcium; s-Klotho, soluble Klotho.
Figure 4. Correlation coefﬁcient between the serum levels of s-Klotho and Ps. r ¼ e0.548, 95% conﬁdence interval e0.680 to e0.383, P ¼ 0.001.
Ps, phosphate; s-Klotho, soluble Klotho.
Figure 2. Correlation coefﬁcient between the serum level of s-Klotho and PTH. r ¼ e0.484, 95% conﬁdence interval e0.630 to e0.306, P ¼ 0.001.
PTH, parathyroid hormone; s-Klotho, soluble Klotho.
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Table 3. Echocardiographic ﬁndings, CIMT, and CAD of the studied patients and control group
Variable All patients (n ¼ 88) Control group (n ¼ 28) P Group I (s-Klotho < 474, n ¼ 44) Group II (s-Klotho > 474, n ¼ 44) P
LVM (g) 193.4 ± 22.3 112.7 ± 23.6 0.001 198.6 ± 26.3 188.2 ± 18.3 0.034
LVMI (g/m2) 110.4 ± 21.5 66.4 ± 21.3 0.001 120.7 ± 23.2 110.2 ± 18.6 0.022
LVEF (%) 49.6 ± 10.2 58.6 ± 6.3 0.001 45.9 ± 10.3 55.2 ± 9.3 0.001
CIMT (mm) 1.0 ± 0.2 0.8 ± 0.2 0.001 1.2 ± 0.2 0.9 ± 0.1 0.001
CAD 58 (65.9) e 36 (81.1) 22 (50.0) 0.004
Data are presented as means ± SD or number (%).
CAD, coronary artery disease; CIMT, carotid intimaemedia thickness; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMI, left
ventricular mass index; s-Klotho, soluble Klotho.
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compared to control subjects [30]. However, it appears that s-
Klotho levels are not completely depleted, even in patients with
ESRD on HD [27e29]. This ﬁnding suggests that in humans, a
basal level of s-Klothomay be produced from other organs than
the kidneys, such as the brain and parathyroid glands, as pre-
viously reported in mice [15,31,32]. Recent studies revealed
that s-Klotho has been decreased in the early stage of CKD, even
before rising of Ps or PTH and emerged as a powerful player in
CaePs homeostasis that is thought to contribute to the high
burden of CVD in CKD patients [5,17]. This study showed
that patients with a low s-Klotho (<476 pg/mL) had a high age
and low RRF compared to Group II, and therewas no signiﬁcant
differences in the mean values of Kt/V between the 2 groups.
Our results are in agreement with the results of Lindberg et al
[28], who reported that patients with high s-Klotho were more
with good RRF, and Sawires et al [29], who reported that there
was no signiﬁcant correlation between s-Klotho and Kt/V and
there was signiﬁcant negative correlation between s-Klotho
and age.
The present study showed that patients with a low
s-Klotho were more often associated with CIMT, LV dysfunc-
tion, and CAD, and it seems that there was independent
association between s-Klotho and CIMT, LVEF, and CAD using
multivariate regression analysis. Our results are in agreement
with results of Kitagawa et al [33] who reported that the
serum Klotho level was found to signiﬁcantly correlate with
markers of CKD-mineral and bone disorder and is an
independent biomarker of arterial stiffness in patients withFigure 5. Correlation coefﬁcient between s-Klotho and LVEF. r ¼ 0.392, 95%
LVEF, left ventricular ejection fraction; s-Klotho, soluble Klotho.CKD. In contrary to our results, Buiten et al [34] reported that
s-Klotho was not independently associated with CVD in
dialysis patients and did not support a direct cardioprotective
effect of s-Klotho.
Many clinical studies have suggested that s-Klotho exerts
strong cardioprotective effects. For instance, s-Klotho has been
shown to protect against vascular calciﬁcations in rodent
models of CKD, whereas in humans without CKD, higher
s-Klotho levels have been related to a lower incidence of
mortality and CVD [28,35e37]. Moreover, low s-Klotho levels
have been associated with increased arterial stiffness in CKD
patients [33]. Further support for a direct role of Klotho in
vascular homeostasis comes from in vitro studies showing
endogenous expression of s-Klotho in human vascular smooth
muscle cells [38]. Interestingly, inhibition of s-Klotho expres-
sion in aortic vascular smooth muscle cells resulted in accel-
erated calciﬁcation of these cells [38]. However, the exact role
of s-Klotho in the progression of CVD in dialysis patients re-
mains to be elucidated.
There many reports that CVD starts to develop in early
stages of CKD and that s-Klotho starts to decrease also in early
stages of CKD. Therefore, patients with ESRD on regular HD
have been exposed to low s-Klotho levels for a prolonged
period, predisposing them to vascular calciﬁcations and
atherosclerosis.
The role of s-Klotho in the development of atherosclerotic
disease in dialysis patients might be overshadowed by the large
amount of other pathophysiological stimuli for CVD prevalent
in these patients, such as obesity, diabetes, dyslipidemia, andconﬁdence interval 0.199e0.556, P ¼ 0.001.
Table 4. Multivariate linear regression analysis of the predictive factors for CIMT, LVM, LVMI, LVEF, and CAD
Variables CIMT LVM LVMI LVEF CAD
b P b P b P b P OR P
s-Klotho e0.213 0.040 e0.184 0.070 e0.123 0.080 0.251 0.040 0.342 0.050
FGF-23 0.132 0.060 0.114 0.070 0.134 0.070 e0.162 0.060 0.451 0.060
T. cholesterol 0.075 0.130 0.033 0.160 0.124 0.080 0.004 0.310 0.312 0.090
Triglycerides 0.046 0.150 0.113 0.090 0.031 0.210 0.006 0.110 0.123 0.110
Bl. glucose 0.012 0.230 0.026 0.140 0.017 0.260 0.015 0.090 0.412 0.060
Adjusted for age, gender, mean blood pressure, and duration of dialysis.
Bl., blood; CAD, coronary artery disease; CIMT, carotid intimaemedia thickness; FGF-23, ﬁbroblast growth factor-23; LVEF, left ventricular ejection
fraction; LVM, left ventricular mass; LVMI, left ventricular mass index; OR, odds ratio; s-Klotho, soluble Klotho; T., total.
Kidney Res Clin Pract 35 (2016) 42e4948hypertension. This might explain the disparity between data
found in rodents with only Klotho deﬁciency and patients
suffering from a wide variety of comorbidities. However, our
study showed that there were no signiﬁcant differences in the
mean values of lipid proﬁle, blood glucose, mean blood pres-
sure, body mass index, and duration of dialysis between the 2
groups. Using multivariate regression analysis, we found that
there was no independent association between FGF-23, blood
glucose, total cholesterol, and triglycerides and CVD markers.
These ﬁndings may explain that s-Klotho seems to be inde-
pendently associated with CIMT, LVEF, and CAD as markers of
CVD.
In our study, s-Klotho is signiﬁcantly correlated with
markers of mineral metabolism, which is consistent with many
studies in CKD patients [5,33] that reported that s-Klotho
correlated negatively with PTH and Ps and positively with Ca,
whereas no correlation was found between s-Klotho and 1,25
dihydroxycholecalciferol and fractional excretion of Ca. Also
our study is consistent with studies in HD patients [34] that
reported that the serum s-Klotho level was signiﬁcantly asso-
ciated with a lower plasma 25 hydroxy vitamin D [25(OH)D]
and lower PTH [29].
In addition, in our study, FGF-23 was signiﬁcantly associated
with markers of mineral metabolism, and FGF-23 was not
independently associated with markers of CVD. Our results are
consistent with studies in HD patients [34] that reported that
FGF-23 showed a strong positive association with Ps and PTH
and FGF-23 was not independently associated with CVD. In
addition, our results are comparable with the results from
studies in CKD patients, where FGF-23 levels correlated posi-
tively with PTH and Ps and negatively with 1,25 dihydrox-
ycholecalciferol and no correlation existed with Ca and
fractional excretion of Ca [5].
This study has some limitations. We studied only a small
sample of patients. Data on dietary Ca, Ps, and
medication intake, which may affect the levels of serum Ps, Ca,
s-Klotho, and FGF-23 were not collected. Ps and PTH were not
statistically analyzed as risk factors for CVD.
In conclusion, the present study showed that patients with a
low s-Klotho were more often associated with increased CIMT,
LV dysfunction, and CAD, and it seems that there was an in-
dependent association between s-Klotho and CIMT, LVEF, and
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